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Equivalence Between Oral
and Intravenous Antibiotics
When Treating Serious
Staphylococcal Infections?
Sir—I read with interest the article by
Schrenzel et al. [1], which compared in-
travenous and oral antibiotic regimens for
the treatment of severe staphylococcal in-
fection. The aim of the study was to show
“the equivalence of the treatments” [1, p.
1287]. Equivalence studies have been
plagued by methodological deficiencies
[2, 3], and this study is no exception.
First, such studies require that a pre-
defined range of equivalence be estab-
lished [4]. The range has to be wide
enough to ensure a reasonable sample size
but narrow enough to ensure practical sig-
nificance. If the authors allow the out-
comes in the oral and intravenous anti-
biotic treatment groups to differ by 30%,
is it still meaningful to call the 2 treat-
ment arms equivalent? The fact that,
midway through the study, the differ-
ences between the 2 groups were noted
to be much smaller does not mean that
the original sample size could be de-
creased. On the contrary, the smaller the
range, the larger the sample size needed
to establish equivalence.
This leads us to the major deficiency of
this study: it was underpowered to detect
equivalence at clinically relevant ranges
(i.e., 5%–20%), and because the investi-
gators were unable to recruit 260 partic-
ipants, the study was even underpowered
to detect equivalence at clinically dubious
ranges (i.e., 30%–40%). A P value 1.05
(i.e., not significant) for the 3 outcomes
measured does not imply equivalence.
This highlights 2 important points: first,
the shortcomings of P values, and second,
the importance of 95% CIs to demonstrate
uncertainty. For example, the relative risk
for the intention-to-treat population was
1.1, with a 95% CI of 0.7–1.6 (i.e., the
range of effectiveness of the oral regimen
varied from being 30% less effective to
being 60% more effective than the intra-
venous regimen in treating staphylococcal
infections) and a P value of .66. If we are
to believe the P value, then we cannot re-
ject the null hypothesis that a significant
difference exists between the 2 treatment
groups. Thus, we must deduce that there
is a difference between intravenous and
oral therapy. The 95% CIs, however, tell
the real story. For all 3 outcomes (inten-
tion-to-treat, clinically evaluable, and mi-
crobiologically evaluable), the range of the
95% CIs far exceeds even the excessive
pre-hoc range of equivalence of 30%. This
article [1] shows how easily an under-
powered study can be misinterpreted as
showing equivalence. The results of this
important study are, unfortunately, in-
conclusive. A reasonable clinician should
not make a decision to use an oral regimen
to treat a serious staphylococcal infection
in one of his patients on the basis of this
study. Although the authors should be
commended for undertaking a most dif-
ficult trial, the conclusions presented in
their article are misleading. The major
benefit of this study is that it provides es-
timates that can be used to power a more
definitive trial.
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Reply to Richards et al.
and Ghanem
Sir—We thank Richards et al. [1] and
Ghanem [2] for their stimulating criti-
cisms of our study [3]. We agree that this
clinical trial has a number of methodo-
logical limitations, including its small
sample size (making it statistically impos-
sible to prove the equivalence of both
treatment regimens) and the pooled anal-
ysis of 2 different study arms. However,
we disagree with several comments by
Richards et al. [1]. First, as suggested in
the CONSORT statement [4], the measure
of effect of a study medication can be ex-
pressed as a risk ratio (or relative risk),
with confidence intervals to indicate the
precision of the treatment effect. Second,
the 95% CIs of the effect estimates in our
study cannot rule out some difference be-
tween the 2 treatment regimens that we
compared. Considering the small differ-
ences in outcome for both treatment reg-
imens, it remains unlikely, however, that
a large, clinically important difference in
failure rates has been missed. Third, we
were surprised that Richards et al. [1] did
not carefully evaluate tables 2 and 3 of our
article [3]. These tables and the related
Results section summarized the per-pro-
tocol analysis, which compared patients
according to the treatment that they ac-
tually received and included only those
clinically and microbiologically evaluable
patients who satisfied the entry criteria
and properly followed the protocol [5].
This per-protocol analysis did not show
results that were different from those of
the intention-to-treat analysis. Finally, we
believe that our study results may still be
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of valuable help for those clinicians who
have used fluoroquinolone-rifampicin
combinations for outpatient treatment of
staphylococcal infections for110 years [6].
Nonetheless, the evidence provided by this
study will need further confirmation in a
large randomized trial.
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Glutamine Supplementation
for Patients with Severe
Cryptosporidiosis
Sir—We read with interest the article by
Bushen and colleagues [1] on the effect
of glutamine supplementation in patients
with AIDS and chronic diarrhea. The au-
thors observed not only a significant
improvement in symptoms but also an
improvement in antiretroviral drug ab-
sorption after oral glutamine supplemen-
tation. We describe a patient with a severe
case of Cryptosporidium diarrhea. A dra-
matic improvement in the patient’s clin-
ical condition was associated with par-
enteral administration of glutamine.
A 30-year-old man with fever, dry
cough, diarrhea, and weight loss of 12 kg
received a diagnosis of HIV infection. His
CD4 cell count was 40 cells/mm3, and his
HIV RNA load was 641,000 copies/mL.
Because of the worsening of diarrhea and
the onset of vomiting, he was admitted
to our hospital (Ospedale Generale; Bol-
zano, Italy) on 25 August 2004. Exami-
nation of stool samples revealed infec-
tion with Cryptosporidium parvum but no
other pathogenic microorganisms. Cryp-
tococci were isolated by culture from CSF,
blood, urine, and sputum samples. In-
duction antifungal treatment consisted of
3 weeks of treatment with liposomal am-
photericin B at a dosage of 3 mg/kg/day,
which was combined, for 2 weeks, with
treatment with flucytosine at a dosage of
100 mg/kg/day and was followed by treat-
ment with difluconazole at a dosage of 200
mg b.i.d.
On 1 September, total parenteral nu-
trition was begun because, despite the
administration of methoclopramide and
omeprazole, the patient’s vomiting was
persistent. Administration of flucytosine
was interrupted for 1 week to see whether
vomiting would lessen, but it did not.
Neither treatment with the antiemetic on-
dansetron, given first at a dosage of 8 mg/
day and then at a dosage of 24 mg/day,
nor sedation with chlordemethyldiazepam
or chlorpromazine reduced the vomit-
ing. The intake of liquids, food, and pills
all prompted vomiting. During week 4
of hospitalization, gastroscopy was per-
formed. Histologic examination of gastric
biopsy specimens revealed multiple cryp-
tosporidia on the surface of and within
the gastric pits. From 15 September
through 19 September, azithromycin, 500
mg/day, was given endovenously to com-
bat Cryptosporidium infection, but there
was no evident reduction in diarrhea. Be-
ginning on 18 September, 14 g of gluta-
mine was added to the parenteral nutri-
tion on a daily basis because of the
persistent diarrhea.
After 5 days of glutamine supplemen-
tation, the frequency of the patient’s bowel
movements decreased from 10 move-
ments/day to 5 movements/day, and fluids
could be taken without vomiting. There-
fore, azithromycin at a dosage of 500 mg/
day po and paromomycin at a dosage of
500 mg t.i.d. were given to treat Crypto-
sporidium infection. Two days later, anti-
retroviral therapy with stavudine, lami-
vudine, and indinavir was commenced.
Indinavir was chosen because it had been
shown to be less toxic for enterocytes
and to directly inhibit the development
of Cryptosporidium species in in vitro ex-
periments [2]. Unfortunately, on the
same day that antiretroviral therapy com-
menced, a central venous catheter had to
be removed because of an entry-side in-
fection with thrombosis of the right jug-
ular vein and part of the subclavian vein.
During the next week, total parenteral
nutrition was stopped. Despite treatment
with azithromycin, paromomycin, and an-
tiretroviral drugs, the patient’s diarrhea
worsened, and his clinical condition be-
came life-threatening. It was impossible,
via the oral route and via the peripheral
vein, to sufficiently replace potassium and
protein that had been lost. Serum potas-
sium levels decreased to 1.9 mEq/L, and
serum albumin levels decreased to 1.8 g/
dL. On 4 October, a Groshong central ve-
nous catheter was placed in the left sub-
clavian vein to provide long-term total
parenteral nutrition. Parenteral nutrition
again included 14 g of glutamine. From
the third to the fourth day of administra-
tion of parenteral nutrition, the loss of
fluids through watery diarrhea was re-
duced from 3.7 L to 1.7 L, and, 2 days
later, diarrhea and vomiting had resolved.
Within 11 days after the start of antiret-
